Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Carbohydrate antigen sialyl-Lewis(a), also known as CA19-9 or sLe^a, is a tetrasaccharide carbohydrate structure that functions as a tumor-associated antigen. It is most widely recognized as a serum biomarker for cancers of the digestive tract, especially pancreatic ductal adenocarcinoma, but is also found in other malignancies such as colon and stomach adenocarcinomas. It acts primarily as a ligand for E-selectin, mediating adhesion between cancer cells and endothelium, a key step in tumor cell extravasation during metastasis.
Monoclonal antibodies targeting sLe^a have been explored for passive immunotherapy and active vaccination strategies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Carbohydrate Antigen Sialyl-Lewis(a) (CA19-9).